Nuveen LLC Takes $915,000 Position in Pulse Biosciences, Inc $PLSE

Nuveen LLC bought a new stake in Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 56,846 shares of the company's stock, valued at approximately $915,000. Nuveen LLC owned approximately 0.08% of Pulse Biosciences as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PLSE. Wells Fargo & Company MN boosted its stake in Pulse Biosciences by 27.1% in the fourth quarter. Wells Fargo & Company MN now owns 11,315 shares of the company's stock valued at $197,000 after acquiring an additional 2,416 shares in the last quarter. Barclays PLC boosted its stake in Pulse Biosciences by 8.5% in the fourth quarter. Barclays PLC now owns 32,881 shares of the company's stock valued at $573,000 after acquiring an additional 2,575 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Pulse Biosciences by 98.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after buying an additional 838 shares during the period. Bank of America Corp DE lifted its stake in shares of Pulse Biosciences by 0.4% during the fourth quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock worth $13,727,000 after buying an additional 2,884 shares during the period. Finally, Deutsche Bank AG lifted its stake in shares of Pulse Biosciences by 65.1% during the fourth quarter. Deutsche Bank AG now owns 16,795 shares of the company's stock worth $292,000 after buying an additional 6,625 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Pulse Biosciences news, CTO Darrin Uecker sold 15,000 shares of Pulse Biosciences stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $16.40, for a total value of $246,000.00. Following the completion of the transaction, the chief technology officer owned 137,872 shares of the company's stock, valued at approximately $2,261,100.80. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 71.50% of the company's stock.

Pulse Biosciences Stock Performance

Shares of Pulse Biosciences stock traded down $0.06 during trading on Friday, hitting $15.11. 71,669 shares of the company's stock were exchanged, compared to its average volume of 170,620. The business has a 50-day simple moving average of $15.50 and a 200-day simple moving average of $16.41. Pulse Biosciences, Inc has a 52-week low of $13.77 and a 52-week high of $25.00. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -14.39 and a beta of 1.68.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).

Analyst Upgrades and Downgrades

Separately, Oppenheimer started coverage on shares of Pulse Biosciences in a research note on Monday, July 7th. They set an "outperform" rating and a $22.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Pulse Biosciences has an average rating of "Buy" and a consensus target price of $22.00.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.